---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-018619"
form_type: "8-K"
ticker: "JUNS"
cik: "0001679628"
company_name: "JUPITER NEUROSCIENCES, INC."
filed_at: "2025-07-10T23:59:59+00:00"
generated_at: "2026-05-18T08:46:25.286920+00:00"
event_type: "other"
sentiment: "positive"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Jupiter Neurosciences regains Nasdaq minimum bid price compliance

## Summary
- Nasdaq confirmed compliance on July 9, 2025 after closing bid price ≥ $1.00 for 13 consecutive days (June 18 – July 8, 2025).
- Company had been notified of deficiency on March 21, 2025 with a 180-day cure period ending September 17, 2025.
- Nasdaq considers the matter closed; common stock (JUNS) continues listing on Nasdaq Capital Market.
- Jupiter is a clinical-stage pharma developing JOTROL resveratrol platform for CNS disorders and longevity products.

## SEC filing metadata
- accession: 0001641172-25-018619
- form_type: 8-K
- ticker: JUNS
- cik: 0001679628
- company_name: JUPITER NEUROSCIENCES, INC.
- filed_at: 2025-07-10T23:59:59+00:00
- event_type: other
- sentiment: positive
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1679628/000164117225018619/0001641172-25-018619-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1679628/000164117225018619/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-018619
- JSON: https://secwatch.observer/filing/0001641172-25-018619.json
- Plain text: https://secwatch.observer/filing/0001641172-25-018619.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.